Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19

Am J Transplant. 2021 Nov;21(11):3808-3810. doi: 10.1111/ajt.16764. Epub 2021 Jul 23.

Authors

Ilies Benotmane^{1

2}, Gabriela Gautier-Vargas¹, Floriane Gallais^{2

3}, Pierre Gantner^{2

3}, Noëlle Cognard¹, Jérôme Olagne¹, Aurélie Velay^{2

3}, Françoise Heibel¹, Laura Braun-Parvez¹, Jonas Martzloff¹, Peggy Perrin¹, Bruno Moulin^{1

2}, Samira Fafi-Kremer^{2

3}, Sophie Caillard^{1

2}

Affiliations

¹ Department of Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France.
² Inserm UMR S1109 Labex Transplantex, Fédération de Médecine Translationnelle, Strasbourg University, Strasbourg, France.
³ Department of Virology, Strasbourg University Hospital, Strasbourg, France.

No abstract available

Publication types

Letter

MeSH terms

Antibody Formation
COVID-19 Vaccines
COVID-19*
Humans
Kidney Transplantation*
RNA, Messenger / genetics
SARS-CoV-2
Transplant Recipients

Substances

COVID-19 Vaccines
RNA, Messenger